BREAST CANCER BASE

The advantages of endocrine therapy
Practice has proved that even breast cancer patients after surgery no visible clinical metastases, but a considerable number of patients already exists subclinical metastases. These lesions may develop into a certain period of clinical metastases and threatened the lives of the patients. At present, the auxiliary has become endocrine therapy after surgery for breast cancer patients to receive long-term chances of survival of the most important, if not the only valuable systemic treatment. Because hormone receptor positive or unknown to the patients, supporting endocrine therapy to reduce the risk of recurrence and death risk was crammed with the role of chemotherapy, and its toxicity is much more relaxed.

According to foreign media reports, British scholars confirmed that in contested Xifen (tamoxifen) for 2-3 years, to switch to a new drug Aromasin (®) treatment can effectively reduce the risk of breast cancer recurrence.

IES responsible for a research project of the British Empire University School of Medicine, director of the Cancer Research Center, said Combs, based on the existing right menopausal breast cancer treatment guidelines for acceptable body of estrogen-positive breast cancer patients after surgery is usually in the five years of fiercely Xifen hormone drug therapy to prevent milk cancer recurrence, and to reduce the mortality rate of patients.

Known to many factors will cause the disease are mainly the following factors :
An age : women, the incidence increases with age and the rise in menarche before the rare before the age of 20 is also rare, but 20 years after the incidence rising rapidly, 45 to 50-year-old high, but it was relatively flat, postmenopausal incidence continued to rise, up to about age 70 peak. Mortality increases with age, the mortality rate after the age of 25 increased gradually until old age has always maintained an upward trend.